Analysts at LADENBURG THALM/SH SH began coverage on shares of Zogenix (NASDAQ:ZGNX) in a research note issued on Thursday, August 23rd, MarketBeat.com reports. The firm set a “buy” rating and a $71.00 price target on the stock. LADENBURG THALM/SH SH’s price objective points to a potential upside of 45.49% from the company’s previous close.

A number of other equities analysts have also weighed in on ZGNX. Stifel Nicolaus increased their target price on Zogenix from $55.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, July 13th. BidaskClub upgraded Zogenix from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 17th. Empire increased their target price on Zogenix from $57.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, July 31st. Mizuho raised their price objective on Zogenix to $69.00 and gave the stock a “positive” rating in a research note on Thursday, July 12th. Finally, Zacks Investment Research lowered Zogenix from a “hold” rating to a “sell” rating in a research note on Thursday, June 21st. Two research analysts have rated the stock with a sell rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $68.40.

NASDAQ ZGNX traded up $0.05 during trading hours on Thursday, hitting $48.80. 374,299 shares of the company traded hands, compared to its average volume of 668,886. Zogenix has a twelve month low of $11.80 and a twelve month high of $62.75.

Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings results on Monday, August 6th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.06. During the same period last year, the firm earned ($0.90) EPS. equities research analysts anticipate that Zogenix will post -3.69 EPS for the current year.

In other news, major shareholder Life Sciences Maste Perceptive acquired 100,000 shares of the business’s stock in a transaction that occurred on Friday, August 10th. The shares were bought at an average price of $52.00 per share, with a total value of $5,200,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Gail M. Farfel sold 7,000 shares of the firm’s stock in a transaction on Wednesday, August 8th. The shares were sold at an average price of $52.62, for a total value of $368,340.00. Following the sale, the executive vice president now directly owns 14,143 shares in the company, valued at approximately $744,204.66. The disclosure for this sale can be found here. Company insiders own 5.00% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its holdings in Zogenix by 761.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,534,645 shares of the company’s stock worth $67,831,000 after buying an additional 1,356,428 shares during the period. Swiss National Bank lifted its holdings in Zogenix by 11.0% during the 1st quarter. Swiss National Bank now owns 56,600 shares of the company’s stock worth $2,267,000 after buying an additional 5,600 shares during the period. TD Asset Management Inc. lifted its holdings in Zogenix by 17.6% during the 2nd quarter. TD Asset Management Inc. now owns 47,400 shares of the company’s stock worth $2,095,000 after buying an additional 7,100 shares during the period. Rhumbline Advisers lifted its holdings in Zogenix by 5.1% during the 1st quarter. Rhumbline Advisers now owns 34,097 shares of the company’s stock worth $1,366,000 after buying an additional 1,659 shares during the period. Finally, Stifel Financial Corp lifted its holdings in Zogenix by 73.0% during the 1st quarter. Stifel Financial Corp now owns 10,189 shares of the company’s stock worth $410,000 after buying an additional 4,299 shares during the period.

Zogenix Company Profile

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Featured Story: Short Selling – Explanation For Shorting Stocks

Analyst Recommendations for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.